Our History

Caretech has a proud heritage of utilizing technological innovation to care for and about those who need access to safe medical procedural equipment, and those who provide that equipment and medications in both controlled and hostile environments.

It was amidst a worldwide concern about the emerging HIV AIDS epidemic, at a time when the Australian Government was grappling with the development of “safe syringe programmes” that Harm Reduction Services Pty Ltd now Caretech Services Pty Ltd (“CTS”) was co-founded.

Since its inception in 2001 the company has maintained a simple and singular focus of the supply of “all items required for a single safe injection episode necessary to prevent the spread of BBVs (blood borne viruses)”.

CTS products were commercially sold through community pharmacies in Western Australia, regulated under a specially granted Government licence enabling the participation of retail pharmacies and pharmaceutical wholesalers.

To enable this business model, CTS independently managed all aspects of the production and supply chain thus gaining unique, intrinsic and valuable insight into each component of the logistical and regulatory pathways for both Pharma and MedTech.

CTS was also compelled, under the terms of its special Government licence, to compile and deliver detailed monthly data to the Department of Health. Due to this unique set of circumstances and these specific requirements from the authorities, CTS was able to analyse all aspects of this new, important, and fast-emerging area of healthcare delivery. The community pharmacies that participated also benefited considerably from this approach, and some 20+ million Sterafit™ units were manufactured and sold in this way.

In the initial stages of HRS and CTS development, our founder was also involved with Magellan Technology Pty Ltd, a part of the Wearne family Magellan Group of Companies, as it was pioneering the development of RFID, AI and various other innovative technologies and associations, and at the time had entertained the synergies of combining or merging divergent technologies.

By 2017, being an active member of both the Medical Technology Association of Australia MTAA and APACMed Singapore, the limitations of current systems had become clearly evident to David and others. Technology had also reached a tipping point: miniaturisation, increased capacities, flexibility and wafer production all could contribute to a realistic and viable holistic system encompassing Pharma and MedTech, utilising a hybrid of technological innovations.

As such the concept of the Strategic Intelligent Packaging SIP™ System was developed.

Harm Reduction

In June 1981, the Australian Government implemented the world’s first Harm Minimisation policy.

“Harm minimisation aims to address alcohol and other drug issues by reducing the harmful effects of alcohol and other drugs on individuals and society. Harm minimisation considers the health, social and economic consequences of AOD use on both the individual and the community as a whole.” Source

The resultant social impact on the community has been significant with very considerable costs saved in lives with the containment of the spread of the HIV Virus, the design and application of innovative pharmaceutical and MedTech supply chain programs and new levels of community engagement. Source

The New South Wales based Needle and Syringe Program was first implemented under Australian Government Harm Minimisation Policy with the potentially emerging epidemic of HIV AIDS. It was originally announced in 1985.

The resulting combination of legislation, government funding, system and product design and emergency program implementation was a radical and swift initiative/response to block the potential cross community spread of the HIV virus which had started spreading at an alarming rate in the community mentioned above in Sydney at that time.

Later transitioning into a nationally sponsored initiative varying from State to State, the evidence now shows that the symbiotic mechanistic relationship of Federal regulatory policy, State government programs and enterprise technological design and innovation created a now demonstrably effective system for containing the spread of a number of very dangerous pathogens and viruses, most especially HIV AIDS and HEPC amongst the targeted high risk community.

The first National HIV/AIDS Strategy released by the Australian Commonwealth Government in 1989 provided a framework for an integrated response to the HIV epidemic and a plan for action across a range of policy and program activities. Needle and Syringe Programs were a key component on the education and prevention strategy.” Professor Richard Feachem, World Bank. Source

The Harm Reduction NSP Model

Needle and Syringe Programs (NSPs) are a proven public health measure to reduce the spread of blood borne viral infections such as HIV and hepatitis C among marginalised communities. The provision targeted and specific MedTech (injecting and procedural equipment) and

the information systems which include, referrals, medical care and social services has enabled significant regulatory, industrial and behavioural change to exploit and enhance the community benefits of the program.

Australian Implementation

The first Australian NSP began in Sydney in 1986 as a trial project. The individual testing of used syringes caught in the medical waste stream returned to the Darlinghurst Program detected an increase in HIV prevalence, suggesting strongly that HIV was spreading among the program’s clients. Therefore, in the following year NSPs became NSW Government policy. Other States and Territories followed soon after, with modes and models of implementation varying between state and territory jurisdictions, and with some between locality and service provider.

Dependent on the State / Territory Health Department policy and/or Community Pharmacy participation and methodology, the proportionate disbursement of Federal Government funds to both State and Territory government and NGO run program participants also varied substantially with the disbursement of Federal (COAG) funds to each State and Territory.

Western Australia – The Commercial Model

In Western Australia, the program was modified under a ‘special exemption’ from the WA Department of Health in agreement with the Pharmaceutical Council of Western Australia (the then Registrar of WA Pharmacies).